Drug Profile

Invobenitug - 4TEEN4 Pharmaceuticals

Alternative Names: AK-1967; Procizumab; Procizumab - 4TEEN4 Pharmaceuticals

Latest Information Update: 21 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator 4TEEN4 Pharmaceuticals
Class Cardiovascular therapies; Monoclonal antibodies
Mechanism of Action DPP3 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Cardiogenic shock

Most Recent Events

16 Jul 2026 Invobenitug receives Fast track status from the US FDA for Cardiogenic shock
15 Jul 2025 4TEEN4 Pharmaceuticals plans a pivotal phase II/III trial for Cardiogenic shock in the second half of 2026
15 Jul 2025 4TEEN4 Pharmaceuticals plans a phase IIa trial for Cardiogenic shock in mid-2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com